GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

TGTX · Sep 30, 2025

TG THERAPEUTICS, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001437749-25-033363General Corporate
Capex intensity45thOwn-history percentile · N=11
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

0.05% · OPTIONAL · VALID

Operating cash generation65thOwn-history percentile · N=17
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-14.32% · OPTIONAL · VALID

Revenue growth54thOwn-history percentile · N=13
Evidence method

Yoy · gp.fundamentals.revenue

92.79% · CORE · VALID

Inventory pressure30thOwn-history percentile · N=10
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

90.87% · OPTIONAL · VALID

Gross margin0thOwn-history percentile · N=8
Evidence method

Level · gp.fundamentals.gross_margin

82.63% · CORE · VALID

Operating margin88thOwn-history percentile · N=17
Evidence method

Level · gp.fundamentals.operating_margin

18.16% · CORE · VALID

R&D intensity24thOwn-history percentile · N=17
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

25.28% · OPTIONAL · VALID

SBC intensity12thOwn-history percentile · N=17
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

10.94% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History17 statesSelf-history eligible
Jun 30, 20220/7 normalizedLevel 3Sep 30, 20220/7 normalizedLevel 3Dec 31, 20220/7 normalizedLevel 3Mar 31, 20230/7 normalizedLevel 3Jun 30, 20235/7 normalizedLevel 3Sep 30, 20235/8 normalizedLevel 3Dec 31, 20235/9 normalizedLevel 3Mar 31, 20244/7 normalizedLevel 3Jun 30, 20245/7 normalizedLevel 3Sep 30, 20245/7 normalizedLevel 3Dec 31, 20246/8 normalizedLevel 3Mar 31, 20257/8 normalizedLevel 3Jun 30, 20257/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20268/8 normalizedLevel 3Jun 30, 20268/8 normalizedLevel 4
Period transition

What moved in the state?

Capex Intensity Increased
Previous
0.03%
Current
0.05%
Delta
0.02%
Cash Generation Decreased
Previous
5.27%
Current
-14.32%
Delta
-19.59%
Growth Increased
Previous
92.13%
Current
92.79%
Delta
0.66%
Inventory Pressure Decreased
Previous
109.96%
Current
90.87%
Delta
-19.08%
Margin Decreased
Previous
86.58%
Current
82.63%
Delta
-3.96%
Profitability Decreased
Previous
24.69%
Current
18.16%
Delta
-6.53%
R And D Intensity Increased
Previous
22.52%
Current
25.28%
Delta
2.76%
Sbc Intensity Decreased
Previous
11.62%
Current
10.94%
Delta
-0.68%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · TGTX Fundamental State →Has State · TG THERAPEUTICS, INC. →Transitioned To · TGTX Fundamental State →Transitioned To · TGTX CAPEX_INTENSITY_INCREASED →Transitioned To · TGTX CASH_GENERATION_DECREASED →Transitioned To · TGTX GROWTH_INCREASED →Transitioned To · TGTX INVENTORY_PRESSURE_DECREASED →Transitioned To · TGTX MARGIN_DECREASED →Transitioned To · TGTX PROFITABILITY_DECREASED →Transitioned To · TGTX R_AND_D_INTENSITY_INCREASED →Transitioned To · TGTX SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.